Abstract
Summary
Hemophilia is a rare, inherited disorder in which blood doesn’t clot normally due to the lack of sufficient blood clotting factor. Clotting factor is a protein required for blood clotting to occur normally.
LPI (LP Information)' newest research report, the “Hemophillia A and B Therapeutics Materials Industry Forecast” looks at past sales and reviews total world Hemophillia A and B Therapeutics Materials sales in 2022, providing a comprehensive analysis by region and market sector of projected Hemophillia A and B Therapeutics Materials sales for 2023 through 2029. With Hemophillia A and B Therapeutics Materials sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hemophillia A and B Therapeutics Materials industry.
This Insight Report provides a comprehensive analysis of the global Hemophillia A and B Therapeutics Materials landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hemophillia A and B Therapeutics Materials portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hemophillia A and B Therapeutics Materials market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hemophillia A and B Therapeutics Materials and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hemophillia A and B Therapeutics Materials.
The global Hemophillia A and B Therapeutics Materials market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
Novel treatments for people suffering from hemophilia and other different bleeding problems has evolved over the past. Hemostasis requires a specific missing plasma protein to prevent unnecessary bleeding, they are named as different factors in the blood. Furthermore, these proteins are contained in concentrate products of lyophilized factor. The analysis in the report describes the purity and viral safety issues for most of the coagulation products currently available along with the market potential. A prompt treatment is required for therapeutic management of bleeding disorders during the bleeding episodes to minimize complications ascending from accumulation of blood in joint spaces that may result in compartment syndrome and have its own complication in health of an individual. There are number of treatment regimens available in the form of non-complicated and complicated bleeding episodes.
This report presents a comprehensive overview, market shares, and growth opportunities of Hemophillia A and B Therapeutics Materials market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Desmopressin
Octocogalfa
Nonacogalfa
Others
Segmentation by application
Hospitals
Ambulatory Surgical Centers
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Arsia therapeutics
Spark Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc.
Sangamo Therapeutics, Inc.
LPI (LP Information)' newest research report, the “Hemophillia A and B Therapeutics Materials Industry Forecast” looks at past sales and reviews total world Hemophillia A and B Therapeutics Materials sales in 2022, providing a comprehensive analysis by region and market sector of projected Hemophillia A and B Therapeutics Materials sales for 2023 through 2029. With Hemophillia A and B Therapeutics Materials sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hemophillia A and B Therapeutics Materials industry.
This Insight Report provides a comprehensive analysis of the global Hemophillia A and B Therapeutics Materials landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hemophillia A and B Therapeutics Materials portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hemophillia A and B Therapeutics Materials market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hemophillia A and B Therapeutics Materials and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hemophillia A and B Therapeutics Materials.
The global Hemophillia A and B Therapeutics Materials market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
Novel treatments for people suffering from hemophilia and other different bleeding problems has evolved over the past. Hemostasis requires a specific missing plasma protein to prevent unnecessary bleeding, they are named as different factors in the blood. Furthermore, these proteins are contained in concentrate products of lyophilized factor. The analysis in the report describes the purity and viral safety issues for most of the coagulation products currently available along with the market potential. A prompt treatment is required for therapeutic management of bleeding disorders during the bleeding episodes to minimize complications ascending from accumulation of blood in joint spaces that may result in compartment syndrome and have its own complication in health of an individual. There are number of treatment regimens available in the form of non-complicated and complicated bleeding episodes.
This report presents a comprehensive overview, market shares, and growth opportunities of Hemophillia A and B Therapeutics Materials market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Desmopressin
Octocogalfa
Nonacogalfa
Others
Segmentation by application
Hospitals
Ambulatory Surgical Centers
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Arsia therapeutics
Spark Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc.
Sangamo Therapeutics, Inc.
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Hemophillia A and B Therapeutics Materials Market Size 2018-2029
2.1.2 Hemophillia A and B Therapeutics Materials Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Hemophillia A and B Therapeutics Materials Segment by Type
2.2.1 Desmopressin
2.2.2 Octocogalfa
2.2.3 Nonacogalfa
2.2.4 Others
2.3 Hemophillia A and B Therapeutics Materials Market Size by Type
2.3.1 Hemophillia A and B Therapeutics Materials Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Hemophillia A and B Therapeutics Materials Market Size Market Share by Type (2018-2023)
2.4 Hemophillia A and B Therapeutics Materials Segment by Application
2.4.1 Hospitals
2.4.2 Ambulatory Surgical Centers
2.5 Hemophillia A and B Therapeutics Materials Market Size by Application
2.5.1 Hemophillia A and B Therapeutics Materials Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Hemophillia A and B Therapeutics Materials Market Size Market Share by Application (2018-2023)
3 Hemophillia A and B Therapeutics Materials Market Size by Player
3.1 Hemophillia A and B Therapeutics Materials Market Size Market Share by Players
3.1.1 Global Hemophillia A and B Therapeutics Materials Revenue by Players (2018-2023)
3.1.2 Global Hemophillia A and B Therapeutics Materials Revenue Market Share by Players (2018-2023)
3.2 Global Hemophillia A and B Therapeutics Materials Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Hemophillia A and B Therapeutics Materials by Regions
4.1 Hemophillia A and B Therapeutics Materials Market Size by Regions (2018-2023)
4.2 Americas Hemophillia A and B Therapeutics Materials Market Size Growth (2018-2023)
4.3 APAC Hemophillia A and B Therapeutics Materials Market Size Growth (2018-2023)
4.4 Europe Hemophillia A and B Therapeutics Materials Market Size Growth (2018-2023)
4.5 Middle East & Africa Hemophillia A and B Therapeutics Materials Market Size Growth (2018-2023)
5 Americas
5.1 Americas Hemophillia A and B Therapeutics Materials Market Size by Country (2018-2023)
5.2 Americas Hemophillia A and B Therapeutics Materials Market Size by Type (2018-2023)
5.3 Americas Hemophillia A and B Therapeutics Materials Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Hemophillia A and B Therapeutics Materials Market Size by Region (2018-2023)
6.2 APAC Hemophillia A and B Therapeutics Materials Market Size by Type (2018-2023)
6.3 APAC Hemophillia A and B Therapeutics Materials Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Hemophillia A and B Therapeutics Materials by Country (2018-2023)
7.2 Europe Hemophillia A and B Therapeutics Materials Market Size by Type (2018-2023)
7.3 Europe Hemophillia A and B Therapeutics Materials Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Hemophillia A and B Therapeutics Materials by Region (2018-2023)
8.2 Middle East & Africa Hemophillia A and B Therapeutics Materials Market Size by Type (2018-2023)
8.3 Middle East & Africa Hemophillia A and B Therapeutics Materials Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Hemophillia A and B Therapeutics Materials Market Forecast
10.1 Global Hemophillia A and B Therapeutics Materials Forecast by Regions (2024-2029)
10.1.1 Global Hemophillia A and B Therapeutics Materials Forecast by Regions (2024-2029)
10.1.2 Americas Hemophillia A and B Therapeutics Materials Forecast
10.1.3 APAC Hemophillia A and B Therapeutics Materials Forecast
10.1.4 Europe Hemophillia A and B Therapeutics Materials Forecast
10.1.5 Middle East & Africa Hemophillia A and B Therapeutics Materials Forecast
10.2 Americas Hemophillia A and B Therapeutics Materials Forecast by Country (2024-2029)
10.2.1 United States Hemophillia A and B Therapeutics Materials Market Forecast
10.2.2 Canada Hemophillia A and B Therapeutics Materials Market Forecast
10.2.3 Mexico Hemophillia A and B Therapeutics Materials Market Forecast
10.2.4 Brazil Hemophillia A and B Therapeutics Materials Market Forecast
10.3 APAC Hemophillia A and B Therapeutics Materials Forecast by Region (2024-2029)
10.3.1 China Hemophillia A and B Therapeutics Materials Market Forecast
10.3.2 Japan Hemophillia A and B Therapeutics Materials Market Forecast
10.3.3 Korea Hemophillia A and B Therapeutics Materials Market Forecast
10.3.4 Southeast Asia Hemophillia A and B Therapeutics Materials Market Forecast
10.3.5 India Hemophillia A and B Therapeutics Materials Market Forecast
10.3.6 Australia Hemophillia A and B Therapeutics Materials Market Forecast
10.4 Europe Hemophillia A and B Therapeutics Materials Forecast by Country (2024-2029)
10.4.1 Germany Hemophillia A and B Therapeutics Materials Market Forecast
10.4.2 France Hemophillia A and B Therapeutics Materials Market Forecast
10.4.3 UK Hemophillia A and B Therapeutics Materials Market Forecast
10.4.4 Italy Hemophillia A and B Therapeutics Materials Market Forecast
10.4.5 Russia Hemophillia A and B Therapeutics Materials Market Forecast
10.5 Middle East & Africa Hemophillia A and B Therapeutics Materials Forecast by Region (2024-2029)
10.5.1 Egypt Hemophillia A and B Therapeutics Materials Market Forecast
10.5.2 South Africa Hemophillia A and B Therapeutics Materials Market Forecast
10.5.3 Israel Hemophillia A and B Therapeutics Materials Market Forecast
10.5.4 Turkey Hemophillia A and B Therapeutics Materials Market Forecast
10.5.5 GCC Countries Hemophillia A and B Therapeutics Materials Market Forecast
10.6 Global Hemophillia A and B Therapeutics Materials Forecast by Type (2024-2029)
10.7 Global Hemophillia A and B Therapeutics Materials Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Arsia therapeutics
11.1.1 Arsia therapeutics Company Information
11.1.2 Arsia therapeutics Hemophillia A and B Therapeutics Materials Product Offered
11.1.3 Arsia therapeutics Hemophillia A and B Therapeutics Materials Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Arsia therapeutics Main Business Overview
11.1.5 Arsia therapeutics Latest Developments
11.2 Spark Therapeutics, Inc.
11.2.1 Spark Therapeutics, Inc. Company Information
11.2.2 Spark Therapeutics, Inc. Hemophillia A and B Therapeutics Materials Product Offered
11.2.3 Spark Therapeutics, Inc. Hemophillia A and B Therapeutics Materials Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Spark Therapeutics, Inc. Main Business Overview
11.2.5 Spark Therapeutics, Inc. Latest Developments
11.3 Alnylam Pharmaceuticals, Inc.
11.3.1 Alnylam Pharmaceuticals, Inc. Company Information
11.3.2 Alnylam Pharmaceuticals, Inc. Hemophillia A and B Therapeutics Materials Product Offered
11.3.3 Alnylam Pharmaceuticals, Inc. Hemophillia A and B Therapeutics Materials Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Alnylam Pharmaceuticals, Inc. Main Business Overview
11.3.5 Alnylam Pharmaceuticals, Inc. Latest Developments
11.4 Sangamo Therapeutics, Inc.
11.4.1 Sangamo Therapeutics, Inc. Company Information
11.4.2 Sangamo Therapeutics, Inc. Hemophillia A and B Therapeutics Materials Product Offered
11.4.3 Sangamo Therapeutics, Inc. Hemophillia A and B Therapeutics Materials Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Sangamo Therapeutics, Inc. Main Business Overview
11.4.5 Sangamo Therapeutics, Inc. Latest Developments
12 Research Findings and Conclusion